Circulating Bacterial DNA in Colorectal Cancer Patients: The Potential Role of

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 29

PMID 39201711

Authors

Ioannis Koliarakis

Ilias Lagkouvardos

Konstantinos Vogiatzoglou

Ioannis Tsamandouras

Evangelia Intze

Ippokratis Messaritakis

John Souglakos

John Tsiaoussis

Affiliations

Soon will be listed here.

Abstract

Intestinal dysbiosis is a major contributor to colorectal cancer (CRC) development, leading to bacterial translocation into the bloodstream. This study aimed to evaluate the presence of circulated bacterial DNA (cbDNA) in CRC patients ( = 75) and healthy individuals ( = 25). DNA extracted from peripheral blood was analyzed using PCR, with specific primers targeting rRNA, (), and (). High rRNA and detections were observed in all patients and controls. Only the detection of was significantly higher in metastatic non-excised CRC, compared to controls ( < 0.001), non-metastatic excised CRC ( = 0.023), and metastatic excised CRC ( = 0.023). This effect was mainly attributed to the presence of the primary tumor ( = 0.006) but not the presence of distant metastases ( = 0.217). The association of cbDNA with other clinical parameters or co-morbidities was also evaluated, revealing a higher detection of in CRC patients with diabetes ( = 0.004). These results highlighted the importance of bacterial translocation in CRC patients and the potential role of as an intratumoral oncomicrobe in CRC.

References

Wassenaar T . E. coli and colorectal cancer: a complex relationship that deserves a critical mindset. Crit Rev Microbiol. 2018; 44(5):619-632. DOI: 10.1080/1040841X.2018.1481013. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Tan C, Ko K, Chen H, Liu J, Loh M, Chia M . No evidence for a common blood microbiome based on a population study of 9,770 healthy humans. Nat Microbiol. 2023; 8(5):973-985. PMC: 10159858. DOI: 10.1038/s41564-023-01350-w. View

Arroyo V, Moreau R, Kamath P, Jalan R, Gines P, Nevens F . Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers. 2016; 2:16041. DOI: 10.1038/nrdp.2016.41. View

Irrazabal T, Belcheva A, Girardin S, Martin A, Philpott D . The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell. 2014; 54(2):309-20. DOI: 10.1016/j.molcel.2014.03.039. View

Kostic A, Gevers D, Pedamallu C, Michaud M, Duke F, Earl A . Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2011; 22(2):292-8. PMC: 3266036. DOI: 10.1101/gr.126573.111. View

Potgieter M, Bester J, Kell D, Pretorius E . The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev. 2015; 39(4):567-91. PMC: 4487407. DOI: 10.1093/femsre/fuv013. View

Yan X, Liu L, Li H, Qin H, Sun Z . Clinical significance of , epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017; 10:5031-5046. PMC: 5652912. DOI: 10.2147/OTT.S145949. View

Zheng D, Liwinski T, Elinav E . Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6):492-506. PMC: 7264227. DOI: 10.1038/s41422-020-0332-7. View

10.

Paisse S, Valle C, Servant F, Courtney M, Burcelin R, Amar J . Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion. 2016; 56(5):1138-47. DOI: 10.1111/trf.13477. View

11.

Messaritakis I, Koulouris A, Boukla E, Vogiatzoglou K, Lagkouvardos I, Intze E . Exploring Gut Microbiome Composition and Circulating Microbial DNA Fragments in Patients with Stage II/III Colorectal Cancer: A Comprehensive Analysis. Cancers (Basel). 2024; 16(10). PMC: 11119035. DOI: 10.3390/cancers16101923. View

12.

Dai Z, Coker O, Nakatsu G, Wu W, Zhao L, Chen Z . Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018; 6(1):70. PMC: 5896039. DOI: 10.1186/s40168-018-0451-2. View

13.

Castellarin M, Warren R, Freeman J, Dreolini L, Krzywinski M, Strauss J . Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2011; 22(2):299-306. PMC: 3266037. DOI: 10.1101/gr.126516.111. View

14.

Mima K, Nishihara R, Qian Z, Cao Y, Sukawa Y, Nowak J . Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2015; 65(12):1973-1980. PMC: 4769120. DOI: 10.1136/gutjnl-2015-310101. View

15.

Lin X, Jiang J, Luo J, Lin C, Ting P, Yang U . The long term microbiota and metabolic status in patients with colorectal cancer after curative colon surgery. PLoS One. 2019; 14(6):e0218436. PMC: 6570030. DOI: 10.1371/journal.pone.0218436. View

16.

Bruns T, Reuken P, Stengel S, Gerber L, Appenrodt B, Schade J . The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int. 2016; 36(8):1133-42. DOI: 10.1111/liv.13095. View

17.

Jin M, Wu J, Shi L, Zhou B, Shang F, Chang X . Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients. Front Microbiol. 2022; 13:993285. PMC: 9607965. DOI: 10.3389/fmicb.2022.993285. View

18.

Genua F, Raghunathan V, Jenab M, Gallagher W, Hughes D . The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development. Front Oncol. 2021; 11:626349. PMC: 8082020. DOI: 10.3389/fonc.2021.626349. View

19.

Carelli L, DAquila P, De Rango F, Incorvaia A, Sena G, Passarino G . Modulation of Gut Microbiota through Low-Calorie and Two-Phase Diets in Obese Individuals. Nutrients. 2023; 15(8). PMC: 10140827. DOI: 10.3390/nu15081841. View

20.

Kong C, Gao R, Yan X, Huang L, He J, Li H . Alterations in intestinal microbiota of colorectal cancer patients receiving radical surgery combined with adjuvant CapeOx therapy. Sci China Life Sci. 2019; 62(9):1178-1193. DOI: 10.1007/s11427-018-9456-x. View